Published in Int J Nanomedicine on February 25, 2013
Subviral particle as vaccine and vaccine platform. Curr Opin Virol (2014) 0.83
A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles. Sci Rep (2016) 0.76
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med (1993) 18.56
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 14.96
Interleukin-2: inception, impact, and implications. Science (1988) 8.19
Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 7.93
Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A (1992) 7.74
T cell response to Mycobacterium tuberculosis. J Infect Dis (1993) 5.53
Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med (1996) 5.36
The population dynamics and control of tuberculosis. Science (2010) 5.08
Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1995) 4.76
Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol (1993) 4.46
Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun (1994) 4.07
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun (2001) 2.62
Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol (2000) 2.61
T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun (1995) 2.57
T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun (1991) 2.43
Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev (1998) 2.36
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun (2000) 2.29
Materials engineering for immunomodulation. Nature (2009) 2.18
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09
Virus-like particles: passport to immune recognition. Methods (2006) 1.89
TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol (2001) 1.79
Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci U S A (1999) 1.79
Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol (1990) 1.74
Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol (1992) 1.73
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Vaccine adjuvants revisited. Vaccine (2007) 1.69
Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol (2001) 1.66
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A (2011) 1.35
Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology (2004) 1.31
Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun (2003) 1.29
Quantitative estimations of five classes of immunoglobulin in inbred mouse strains. Immunology (1977) 1.27
Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett (1999) 1.12
Determinants of vaccine-induced resistance in animal models of pulmonary tuberculosis. Scand J Infect Dis (2001) 1.11
Polymeric particles in vaccine delivery. Curr Opin Microbiol (2010) 1.11
Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. J Virol (2003) 1.10
Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine (2001) 1.10
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine (1995) 1.06
Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infect Immun (2008) 1.02
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol (2005) 1.01
Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol (2010) 0.99
In vitro assembly of mosaic hepatitis B virus capsid-like particles (CLPs): rescue into CLPs of assembly-deficient core protein fusions and FRET-suited CLPs. FEBS Lett (2005) 0.98
Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine (2006) 0.93
Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol (2002) 0.89
Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng. Vaccine (2005) 0.89
Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine (2012) 0.88
Peptide-based subunit nanovaccines. Curr Drug Deliv (2011) 0.84
Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) (2006) 0.84
Epitope based recombinant BCG vaccine elicits specific Th1 polarized immune responses in BALB/c mice. Vaccine (2011) 0.83
Purification of E. coli-expressed HIS-tagged hepatitis B core antigen by Ni2+ -chelate affinity chromatography. J Virol Methods (1999) 0.83
Mycobacterium tuberculosis culture filtrate protein 10-specific effector/memory CD4⁺ and CD8⁺ T cells in tubercular pleural fluid, with biased usage of T cell receptor Vβ chains. Infect Immun (2011) 0.82
A novel recombinant Mycobacterium bovis bacillus Calmette-Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity. Acta Biochim Biophys Sin (Shanghai) (2011) 0.82
Characterization of immune responses following intranasal immunization with the Mycobacterium bovis CFP-10 protein expressed by attenuated Salmonella typhimurium. Scand J Immunol (2010) 0.78
Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses. Vaccine (2011) 0.77
Identification of moaA3 gene in patient isolates of Mycobacterium tuberculosis in Kerala, which is absent in M. tuberculosis H37Rv and H37Ra. BMC Infect Dis (2005) 0.96
Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol Adv (2009) 0.95
Whole-genome sequences of two clinical isolates of Mycobacterium tuberculosis from Kerala, South India. J Bacteriol (2012) 0.92
Deciphering sulfoglycolipids of Mycobacterium tuberculosis. J Lipid Res (2011) 0.89
Molecular epidemiology of Mycobacterium tuberculosis isolates from Kerala, India using IS6110-RFLP, spoligotyping and MIRU-VNTRs. Infect Genet Evol (2013) 0.85
Ethyl p-methoxycinnamate isolated from a traditional anti-tuberculosis medicinal herb inhibits drug resistant strains of Mycobacterium tuberculosis in vitro. Fitoterapia (2011) 0.85
Synthesis, antimicrobial, antimycobacterial and structure-activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b]indoles. Eur J Med Chem (2011) 0.83
Standardization and evaluation of a tetraplex polymerase chain reaction to detect and differentiate Mycobacterium tuberculosis complex and nontuberculous Mycobacteria--a retrospective study on pulmonary TB patients. Diagn Microbiol Infect Dis (2011) 0.80
Combined use of Amplified Fragment Length Polymorphism and IS6110-RFLP in fingerprinting clinical isolates of Mycobacterium tuberculosis from Kerala, South India. BMC Infect Dis (2007) 0.79
Presence of region of difference 1 among clinical isolates of Mycobacterium tuberculosis from India. J Clin Microbiol (2007) 0.79
A systems biology approach to model neural stem cell regulation by notch, shh, wnt, and EGF signaling pathways. OMICS (2011) 0.78
Bioconversion of sodium dodecyl sulphate to rhamnolipid by Pseudomonas aeruginosa: a novel and cost-effective production strategy. Appl Biochem Biotechnol (2012) 0.77
Comparative analysis of mycobacterial truncated hemoglobin promoters and the groEL2 promoter in free-living and intracellular mycobacteria. Appl Environ Microbiol (2012) 0.76
Mycobacterium tuberculosis in Wild Asian Elephants, Southern India. Emerg Infect Dis (2017) 0.75
Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage. Int J Nanomedicine (2013) 0.75
Quantitative evaluation of left ventricle performance from two dimensional echo images. Echocardiography (2006) 0.75
Detection of left ventricle systolic dysfunction from shape deformity. Australas Phys Eng Sci Med (2005) 0.75
Do Mycobacterium marinum infections occur in India? Indian J Dermatol Venereol Leprol (2010) 0.75